• Bolsas y Mercados Españoles highlights Labiana Health’s performance since joining BME Growth and its consolidation as an international pharmaceutical group.
• The company strengthens its position as a Spanish pharmaceutical company specializing in human health, animal health, and contract development and manufacturing (CDMO).

Madrid, February 25, 2026 – Labiana Health has been recognized as a success story on BME Growth by Bolsas y Mercados Españoles (BME), which highlights the company’s evolution since its IPO and its growth as a pharmaceutical group specializing in human and animal health, being the first veterinary pharmaceutical laboratory to be listed on the stock exchange in Spain.

The article published by BME analyzes Labiana Health’s trajectory since its incorporation into BME Growth in 2022, highlighting the company’s development as a Spanish pharmaceutical company with an international presence and a diversified business model.

With more than 60 years of experience in the pharmaceutical sector, Labiana Health has established itself as a group specializing in human health, animal health, and contract development and manufacturing (CDMO), with commercial activity in more than 120 countries.

Labiana Health currently has more than 50 proprietary medicines and maintains industrial relationships with more than 300 international pharmaceutical companies, offering comprehensive services that include research, development, manufacturing, and distribution.

The IPO on BME Growth drives Labiana Health’s growth

As highlighted by BME in an interview with Manuel Ramos, CEO of the company, Labiana Health’s incorporation into the BME Growth market has helped to strengthen the company’s positioning, improving its access to financing and its visibility among national and international investors.

Being listed on the stock exchange has enabled Labiana Health to make progress in:

• Strengthening its financial structure;
• Improving transparency and corporate governance;
• Increasing its visibility in capital markets;
• Supporting international growth.

This process has accompanied the company’s industrial development and the expansion of its global presence.

Pharmaceutical business model based on animal health, human health, and CDMO

Labiana Health’s model combines the marketing of its own medicines with pharmaceutical manufacturing for third parties (CDMO), which allows it to diversify its income and establish stable, long-term relationships with international pharmaceutical companies.

Its industrial capabilities include the production of injectable medicines and the development of antibiotics such as Fosfomycin Trometamol, which is marketed in numerous international markets and is one of the world leaders in this active ingredient.

Stock market performance on BME Growth

The article published by BME also highlights Labiana Health’s stock market performance, which has positioned it as the stock that grew the most on BME Growth in 2024 and one of the top performers in 2025, reflecting investors’ growing interest in the company’s business project.

Labiana Health, a Spanish pharmaceutical company with an international outlook

Labiana Health is a Spanish pharmaceutical group specializing in solutions for human and animal health, with a clear international focus and a strategy based on innovation, industrial development, and sustainable growth.

Its recognition as a success story on BME Growth reinforces Labiana Health’s position as a growing listed pharmaceutical company in the Spanish market for small and medium-sized companies.

The full article can be found here:

https://www.bolsasymercados.es/es/bme-exchange/historias-exito/labiana-caso-de-exito-bm-growth.html